We are live on ! Find out more
EBS icon

Emergent Biosolutions
EBS

238 hedge funds and large institutions have $1.88B invested in Emergent Biosolutions in 2017 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 104 increasing their positions, 60 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

373% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 11

73% more repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 60

25% more capital invested

Capital invested by funds: $1.5B → $1.88B (+$378M)

20% more funds holding

Funds holding: 198 → 238 (+40)

7.58% more ownership

Funds ownership: 90% → 97.58% (+7.6%)

47% less call options, than puts

Call options by funds: $684K | Put options by funds: $1.29M

Holders
238
Holders Change
+40
Holders Change %
+20.2%
% of All Funds
5.4%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
52
Increased
104
Reduced
60
Closed
11
Calls
$684K
Puts
$1.29M
Net Calls
-$609K
Net Calls Change
-$1.63M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$24.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$18.2M
3
AAMU
Amundi Asset Management US
Massachusetts
+$14.9M
4
O
OppenheimerFunds
New York
+$13.6M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$11.1M

Top Sellers

Rank Fund Capital Flow
1
GT
Glenmede Trust
Pennsylvania
-$22.3M
2
Fidelity International
Fidelity International
Bermuda
-$11.2M
3
Charles Schwab
Charles Schwab
California
-$6.03M
4
GAM
Gotham Asset Management
New York
-$4.93M
5
Bank of America
Bank of America
North Carolina
-$4.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$210M +$3.93M +93,349 +2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$167M -$252K -5,975 -0.2%
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
$104M +$941K +22,352 +1%
Aberdeen Group
4
Aberdeen Group
United Kingdom
$82M +$2.82M +66,909 +4%
Renaissance Technologies
5
Renaissance Technologies
New York
$73.7M +$18.2M +432,300 +38%
State Street
6
State Street
Massachusetts
$69.6M +$3.46M +82,220 +6%
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$67.2M +$3.57M +84,713 +6%
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$58M +$5.25M +124,698 +11%
SCM
9
Snyder Capital Management
California
$57.7M +$6.08M +144,332 +13%
Northern Trust
10
Northern Trust
Illinois
$48M -$322K -7,653 -0.7%
GT
11
Glenmede Trust
Pennsylvania
$45.7M -$22.3M -528,961 -35%
Goldman Sachs
12
Goldman Sachs
New York
$36.5M +$24.3M +577,036 +277%
Invesco
13
Invesco
Georgia
$36.3M -$2.6M -61,779 -7%
RHJA
14
Rice Hall James & Associates
California
$35.7M +$5.31M +126,069 +20%
LSV Asset Management
15
LSV Asset Management
Illinois
$34.7M +$3.83M +90,971 +14%
Millennium Management
16
Millennium Management
New York
$32.9M +$2.71M +64,321 +10%
Manulife (Manufacturers Life Insurance)
17
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$31.8M +$1.49M +35,317 +5%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$26.6M +$804K +19,105 +3%
Norges Bank
19
Norges Bank
Norway
$24M +$3.07M +72,953 +16%
Federated Hermes
20
Federated Hermes
Pennsylvania
$22.8M +$11.1M +262,729 +115%
UBS AM
21
UBS AM
Illinois
$22.4M -$3.02M -71,713 -13%
Charles Schwab
22
Charles Schwab
California
$22M -$6.03M -143,345 -23%
Russell Investments Group
23
Russell Investments Group
United Kingdom
$21.3M -$328K -7,800 -2%
Fisher Asset Management
24
Fisher Asset Management
Washington
$20M -$131K -3,112 -0.7%
PCM
25
Peregrine Capital Management
Minnesota
$17M -$3.73M -88,687 -19%
1
2 3 4 5

EBS Hedge Fund Activity: Q4 2017 in Review

238 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2017, worth a combined $1.88B — up 25% from $1.5B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new EBS positions and 11 closed out — a net gain of 41 holders — while 104 added to existing stakes and 60 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $24.3M. The largest seller was Glenmede Trust, cutting an estimated $22.3M.

  • 238 institutional investors held Emergent Biosolutions (EBS) as of Q4 2017, up from 198 in Q3 2017.
  • Funds reported $1.88B of Emergent Biosolutions stock for Q4 2017, up 25% quarter-over-quarter.
  • 52 funds opened new Emergent Biosolutions positions in Q4 2017 and 11 closed out, a net change of +41 holders.
  • The largest Emergent Biosolutions buyer in Q4 2017 was Goldman Sachs, an estimated $24.3M added.
  • The largest Emergent Biosolutions seller in Q4 2017 was Glenmede Trust, an estimated $22.3M sold.

Based on aggregated 13F filings for Q4 2017.